Total Funding
46
50
Total FundingDebt Financing raised
Growth Score
-10 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
21019
Kerecis is a commercial stage company pioneering the use of fish skin and fatty acids in cellular-therapy and regenerative-medicine
Acquired by 
Coloplast
Gudmundur Fertram Sigurjonsson: Founder, President & CEOPast Role: Ossur, Head, Wound Management
Dora Gisladottir: VP Product Development and RegistrationPast Role: University of California, Santa Barbara, Chemical Engineer
About the Company
Kerecis develops patented fish-skin products to heal the human body. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish skin is only gently processed and retains its similarity to human skin, making it an ideal substitute for human skin. More than 50 studies have been done on Kerecis technology. Those
studies include two double-blind, comparative, randomized control trials, where fish skin treatment was more efficacious than mammalian-based treatments.
Kerecis is also developing products for areas such as oral surgery, plastic surgery, and neurological applications. The company's products utilize multiple patented fish-skin and fatty-acid technologies to protect and regenerate tissue.
